Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 14/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4457274 | 0.94 | CASP1 (0.47) | CASP1 | |
| SCHEMBL8398037 | 0.94 | CASP1 (0.47) | CASP1 | |
| SCHEMBL1409729 | 0.86 | CASP1 (0.48) | CASP1 | |
| SCHEMBL645654 | 0.82 | CASP1 (0.48) | CASP1 | |
| SCHEMBL644624 | 0.82 | CASP1 (0.48) | CASP1 | |
| SCHEMBL12522514 | 0.80 | CASP1 (0.63) | CASP1 | |
| SCHEMBL949463 | 0.80 | CASP1 (0.63) | CASP1 | |
| SCHEMBL12450829 | 0.77 | CASP1 (0.53) | CASP1 | |
| SCHEMBL646855 | 0.75 | CASP1 (0.50) | CASP1SMN1; SMN2 | |
| SCHEMBL8764106 | 0.75 | SMN1; SMN2 (0.47) | CASP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317414-A2 | GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 | Merck Frosst Canada & Co. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-6525025-B2 | Controlling apoptosis; cardiovascular disorders; central nervous system disorders | MERCK FROSST CANADA & CO. (CA) | 2003-02-25 | — | — | US | disclosed |
| US-20020165230-A1 | Gamma-ketoacid dipeptides as inhibitors of caspase-3 | MERCK CANADA INC. (CA) | 2002-11-07 | — | — | US | disclosed |
| WO-2002020465-A2 | GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 | MERCK FROSST CANADA & CO. (CA) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165230-A1 | Gamma-ketoacid dipeptides as inhibitors of caspase-3 | CASP3, CASP1, CASP10 | CASP1 2/4885LMNA 748/4885SMN1; SMN2 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.